Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Article
Next
Article

Stem Cells in Acute Lymphoblastic Leukaemia

European Oncology & Haematology, 2012;8(3):196-200 DOI: https://doi.org/10.17925/EOH.2012.08.3.196

Abstract

There has been significant debate over the identity of cancer stem cell populations in acute lymphoblastic leukaemia (ALL), with different groups reporting seemingly contradictory results. The latest findings suggest that tumour-propagating capacity is found within a high percentage of ALL blasts and that these cells have diverse immunophenotypes, which suggests that ALL follows a stochastic cancer stem cell model – as opposed to a hierarchical model. Recent data add a layer of complexity to the tumour evolution process by showing that the leukaemia-propagating compartment consists of multiple genetically diverse subclones related by Darwinian-style evolutionary trees. Differences in the cell of origin may also affect tumour development. In this article, we discuss the applicability of cancer stem cell models to ALL in the context of these recent findings.

Keywords

Cancer stem cells, acute lymphoblastic leukaemia, clonal evolution, cell of origin

Received

May 02, 2012

Accepted

2012-07-24T00:00:00

Correspondence

Josef Vormoor, Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Sir James Spence Institute, 4th floor, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK. E: h.j.vormoor@ncl.ac.uk

In the early 1990s, pioneering work from John Dick’s laboratory demonstrated that only a rare subset of malignant acute myeloid leukaemia (AML) cells could reconstitute the disease following successive xenotransplantations in mice.1 This work was possible due to critical advances in haematopoietic stem cell (HSC) isolation based on surface marker expression profiles,2 and provided the first experimental evidence for a concept that had been previously discussed for decades: the cancer stem cell (CSC). The CSC model contends that long-term tumour growth is driven by a population of cells with stem cell-like properties, resulting in the formation of tumours that are functionally and morphologically heterogeneous.

This heterogeneity can be explained by two CSC models. In the hierarchical model, CSCs are a biologically distinct subset of cells that both sustain the stem cell pool through self-renewal and give rise to progeny lacking extensive proliferative capacity. This model is analogous to the function of stem cells in normal tissue development. It follows from this that elimination of the CSC compartment will result in cessation of tumour growth. In contrast, the stochastic model contends that all cells within a tumour have the potential to act as CSCs and that functional heterogeneity is influenced by other factors. These could be either intrinsic (e.g., varying levels of particular transcription factors) or extrinsic (e.g., the tumour niche).

There is a substantial amount of evidence that the hierarchicalmodel applies in some tumours. The initial findings of John Dick’s laboratory, which have since been expanded upon,3 showed that the long-term tumour-maintaining capacity in AML lies only within a rare subpopulation. Although other studies suggest the phenotype of these cells may be more diverse than initially thought,4,5 the bulk of the evidence indicates that AML follows a hierarchical stem cell model. Xenotransplantation studies have also demonstrated that other solid tumours follow the hierarchical model, including breast,6 colon7,8 and brain9 cancers. However, it appears that the model may not apply to all tumours, as the frequency of propagating cells in melanoma is very high (one in four)10 and stem cell activity is associated with all cellular phenotypes11 – although contradictory findings have been reported.12

To view the full article in PDF or eBook formats, please click on the icons above.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.